Post Profile






Biomarker Of Tamoxifen Resistance In Breast Cancer Identified

New research led by the University of Manchester in the UK has found a biomarker or molecular "flag" in women with breast cancer who do not repond, or who have become resistant, to treatment with the hormone drug tamoxifen. The researchers say their discovery will help doctors predict which breast cancer patients are likely to respond best to complementary (adjuvant) hormone therapy with tamoxifen.
read more

share

Related Posts


HDAC inhibitor may overcome resistance to common breast cancer drug

Academics / General Science : Science Codex

SAN FRANCISCO — Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer. They also found...

New drug combination shows promise for breaking breast cancer resistance

Academics / General Science : ScienceDaily: Science Society

A new combination of drugs has been developed that may overcome treatment resistance and relapse in breast cancer. While most women initially respond well to hormonal treatment with drugs such as tamoxifen, many go on to develop res...

Roswell Park Researchers Identify Novel Prognostic Biomarker For Breast And Prostate Cancer

Health : Medical News Today

Roswell Park Researchers Identify Novel Prognostic Biomarker for Breast and Prostate Cancer A significant number of breast and prostate cancers eventually become resistant to current treatment approaches.

Resistance To Common Breast Cancer Drug May Be Overcome By Histone Deacetylase Inhibitor

Health : Medical News Today

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer. They also found that introducin...

Scientists unravel resistance to breast cancer treatment

Academics / General Science : Science Codex

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen. Tamoxifen – used alongside traditional chemotherapy and radiotherapy – blocks the f...

Comments


Copyright © 2016 Regator, LLC